Yasuchika Hasegawa, president of Takeda Pharmaceutical, had a vision to make the top tier of Takeda in oncology in 2015. In 2008, Takeda acquired Millennium Pharmaceuticals, Oncology respected company with annual sales of $ 528 million in 2007 and is a promising new drugs. Hasegawa and Millennium General Director Deborah Dunsire is believed that it was critical for the serial vision within Takeda Millennium Development Goals and to help employees have a positive attitude towards the future of the company. Millennium will operate independently from each other and become Takeda "Center of Excellence in the field of oncology." This is considered the steps that Hasegawa took to successfully integrate the millennium. His priorities are focused on maintaining the Millennium talent and solutions tensions that arose from two very different corporate cultures. He also used the opportunity to turn risk culture Takeda in more innovative and flexible that will support Takeda is a truly global pharmaceutical company. "Hide
by Charles O'Reilly, Asaka Ito, Hiromichi Kimura, Chris D Beaumont, Robert Kneller Source: Stanford Graduate School of Business 13 pages. Publication Date: Mar 06, 2012. Prod. #: OB83B-PDF-ENG
Related Case Solutions & Analyses:
Airbnb
China or the World Financial Reporting Strategy for Hong Kongs Capital Markets
Millennium Pharmaceuticals Inc. (B)
DIENA
Transformation of Pratt & Whitney North Haven (Abridged)
Agnico Eagle Mines
P&G Japan: The SK-II Globalization Project
ANALYSIS OF M & M PIZZA PROPOSAL
Introduction to AAA framework
ACCOUNTING ASSIGNMENT
